INS and familial pancreatic carcinoma: In another study, the administration of pioglitazone, insulin and its analogues to the diabetic patients were found to be associated with increased risk of pancreatic cancer by 45%, hepatic cancer by 32% and pulmonary cancer by 18% as compared to the non-users.